Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.

world map country flags marked pin city pinpoint . mark the route for America
Companies Are Mapping Out New Ways To Treat CF Patients • Source: Shutter Stock

There is little doubt that Vertex Pharmaceuticals Inc.’s cystic fibrosis transmembrane conductance regulator (CFTR) modulators Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) have changed the face of treatment for cystic fibrosis patients. With the approval of Symdeko (tezacaftor), the base therapy for a triple combination with next-generation CFTR modulators, Vertex’s rule of what is forecast to be an $8.6bn market by 2025 is clear for the foreseeable future.

Vertex’s control of the CF market using its triple combination of CFTR modulators is set to carry on for at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category